Comparative study between Nano-surface Polyzene F and drug eluting stents in acute coronary syndrome patients with one-month dual antiplatelet therapy: Immediate and one-year clinical outcome.

Background and objectives : The current clinical practice advocates dual antiplatelet therapy (DAPT) for a year after stent thrombosis (ST) segment elevation myocardial infarction (STEMI), primarily owing to persistent thrombotic risk. The novel COBRA PzF coronary stent was developed to reduce ST risk. The primary goal of the current research was to compare the ef fi cacy and safety of the novel nanocoated PzF stenting with one-month DAPT against 12-month DAPT after the current drug-eluting stent (DES) in STEMI patients and single-vessel coronary artery disease (CAD). Patients and methods : A prospective observational study enrolled 100 cases presented with STEMI and single vessel CAD. Eligible patients were allocated into 2 groups; group I consisted of 50 patients managed with the COBRA PzF stent who received one-month DAPT. Group II consisted of 50 patients treated with DES who received one-year DAPT. The occurrence of ST was our primary endpoint. The secondary endpoints were target vessel revascularization and major adverse cerebro-cardiovascular occurrences throughout the year. Results : There were no observed cases of de fi nite ST in group I against three in group II, however, it did not reach statistical signi fi cance ( P ¼ 0.094) The incidence of target vessel revascularization (6% against 10%), death (2% versus 4%), stroke (0 versus 2%) and major bleeding (0% versus 4%) observed in group I and II, respectively, however, it did not reach statistical signi fi cance. Conclusion : The COBRA Polyzene-F stent with one-month DAPT met the performance goals for ST in patients presenting with STEMI with single vessel CAD and compared favorably with the commercially available DES with one-year DAPT.